Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + lenvatinib neoadjuvant therapy for resectable hepatocellular carcinoma
ChiCTR2400080080Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Jan 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of adebrelimab and lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoint: 1-year recurrence-free survival. Started Jan 2024; status: recruiting.
02
Drugs
adebrelimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400080080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080080.